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Germ cells undergo comprehensive epigenetic reprogramming toward acquiring fitness for pluripotency and
totipotency. Notably, the full extent of the epigenetic reprogramming experienced by germ cells remains
unmatched by attempts to experimentally restore pluripotency in somatic cells. We propose that the defects
present in experimentally generated cells are corrected upon differentiation into the germ cell lineage, as has
been observed in cases of germline transmission. Unraveling the mechanisms responsible for germ cell-
specific epigenetic reprogramming will likely have important implications for both basic and clinical stem
cell research.Epigenetic reprogramming of somatic cells, for example, by
nuclear transplantation into an oocyte, frequently leads to
defects in the resulting conceptus and cells (Hochedlinger and
Jaenisch, 2002; Tamashiro et al., 2003). Many of these defects
are eliminated upon transmission through the germline, suggest-
ing that they are epigenetic in nature and reversible (Shimozawa
et al., 2002; Tamashiro et al., 2002). Cells derived via recent
advances in reprogramming, including experimentally induced
pluripotent stem cells (iPSCs), require critical evaluation of their
properties with respect to the events in the germline, given that
these cells may lack all of the attributes of an authentic pluripo-
tent state. Here, we discuss our growing knowledge of the
mammalian germ cell lineage and the implications of these find-
ings to the experimental manipulation of epigenetic states.
The Foundation of the Germ Cell Lineage
Primordial germ cells (PGCs) originate during development from
postimplantation epiblast cells, which, in turn, arise from the
pluripotent primitive ectoderm cells of the inner-cell mass
(PEct/ICM) of blastocysts (McLaren and Lawson, 2005). Devel-
opment of the postimplantation epiblast is accompanied by
epigenetic modifications that are generally irreversible, including
X inactivation when this chromosome switches from early to late
replication (Takagi et al., 1982); this alteration is perhaps a hall-
mark of genome-wide irreversible epigenetic changes and may
involve DNA methylation. Other changes, including histone
modifications and DNA methylation, also ensue during differen-
tiation of the epiblast and appear to be required in that their
absence in the wake of mutation to several key epigenetic regu-
lators results in early embryonic lethality (Surani et al., 2007).
Thus, PGCs originate from epiblast cells that have initiated the
process of differentiation toward somatic cell lineages (Ohinata
et al., 2005), as reflected in their transcriptional profile.
Whereas the majority of epiblast cells continue to develop
toward diverse somatic fates, this trend is arrested in a few
epiblast cells destined to form the PGCs (Figure 1). Blimp1/
Prdm1, a transcriptional repressor and the key germ cell deter-
minant in mammals, initiates the reversion of differentiating
epiblast cells by repressing the somatic program and initiatingthe germ cell program at embryonic day (E) 6.25 (Ohinata
et al., 2005). Additional changes follow, including re-expression
of pluripotency genes such as Nanog and Sox2 (Yabuta et al.,
2006; Yamaguchi et al., 2005) in nascent PGCs, but not in the
other differentiating epiblast cells. These adjustments suggest
a trend toward reversion to an earlier ICM-like epigenetic state
(Figure 1), although nascent PGCs still possess some character-
istics of epiblast cells, such as an inactive X chromosome (Chuva
de Sousa Lopes et al., 2008; de Napoles et al., 2007; Sugimoto
and Abe, 2007). This epigeneticmemory of the cell’s initial trajec-
tory toward a somatic fate is erased progressively in PGC
precursors.
Epigenetic Reprogramming in the Emerging Germ Cells
Epigenetic reprogramming events commence immediately after
PGC specification at E7.25, which is marked by the detection
ofStella/Dppa3 (Saitouet al., 2002;Sato et al., 2002). These epige-
netic changesare accompaniedbydownregulationof genes impli-
cated in DNA methylation and changes in histone modifications
(Yabuta et al., 2006). Notably, genes, including Glp and Dnmt3b,
are downregulated. As a result, a global loss of histone H3 lysine
9 (H3K9me2) methylation is observed in PGCs between E7.5 and
E8.5, whereas the Ezh2-dependent H3K27me3 modification is
accentuated (Hajkova et al., 2008; Seki et al., 2005). Although the
specific loci remodeled by these global histone modifications in
PGCs remain to be elucidated, the overall effect in PGCs is to shift
themtoward the ICM/ESC-likeepigeneticstate. Indeed,with these
changes, PGCs acquire the potential to dedifferentiate into plurip-
otent embryonic germ (EG) cells that are virtually identical to ESCs
(seebelow). There are nopublished reports on the derivation of EG
cells fromPGCs prior to E8.5, which may indicate the significance
of resetting the epigenome between E7.5 and E8.5 in nascent
PGCs (Figure 1). Recent evidence demonstrates that Prdm14,
another PR domain-containing transcriptional regulator that is de-
tected shortly after Blimp1/Prdm1 in PGC precursors, plays
a pivotal role in regulating epigenetic changes in nascent PGCs.
Gene disruption of Prdm14 hampers both the loss of H3K9me2
and theenhancementofK3K27me3.Consequently,PGCdevelop-
ment and the derivation of EG cells are impaired in the Prdm14Cell Stem Cell 4, June 5, 2009 ª2009 Elsevier Inc. 493
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Prdm14 appear towork in tandem to repress the somatic program
and initiate the germ cell-specific epigenetic program.
Coupled with the global epigenetic modifications that are
observed in PGCs, some key pluripotency genes are also re-
expressed. Included in this list are Nanog and Sox2 (Yabuta
et al., 2006; Yamaguchi et al., 2005), which are normally repressed
in postimplantation epiblast cells and are the very factors involved
in the reversion of somatic cells to pluripotent stem cells (Silva
et al., 2006; Takahashi and Yamanaka, 2006). A recent study
also reveals that the binding of Nanog, Oct4, and Sox2 to
a regulatory element of Xist, a noncoding RNA, may help to
induce reactivation of the X chromosome (Navarro et al., 2008).
However, reactivation of the X chromosome occurs in a pro-
tracted manner in PGCs compared to PEct; X reactivation
commences at around E7.0 and is not completed until E12.5
in PGCs, but it occurs within a day in PEct (Mak et al., 2004;
Okamoto et al., 2004). This difference may be because Xist
repression in PEct involves histone modifications, but the late
replication of the X chromosome in epiblast cells (Takagi et al.,
1982) may be coupled with DNA methylation, which is initially
inherited by nascent PGCs.
The Relationship between Germ Cells
and Pluripotent Stem Cells
As described above, reprogramming in early germ cells results in
PGCs from E8.5–E11.5 embryos being in a permissive state with
respect to their potential to give rise to pluripotent EG cells. EG
cells are virtually identical to ESCs, except for the loss of DNA
methylation from imprinted gene loci in EG cells (Shovlin et al.,
2008; Tada et al., 2001). Both ESCs and EG cells have two active
X chromosomes in female cells, can contribute to chimeras and
the germline, and have transcriptomes that are very similar (Shar-
ova et al., 2007). Despite their similarities, EG cells and ESCs
have distinctive origins from PGC and PEct, respectively. PGCs
are the founders of a unipotent lineage that generates sperm
and eggs only, whereas PEct give rise to all of the somatic fetal
Figure 1. Stepwise Differentiation and
Reprogramming during Mouse
Development
A totipotent zygote develops into a blastocyst,
followed by differentiation into ICM/PEct and
trophectoderm (TE). ICM/PEct are pluripotent
cells but no longer totipotent. After implantation,
ICM/PEct differentiates into the epiblast, coupled
with random X inactivation, a hallmark of the
epigenetic state of this population. During gastru-
lation, epiblast cells give rise to both germ cells
and somatic cells. Whereas somatic cells undergo
further differentiation, PGCs revert to a state that
resembles the ICM/PEct population, with the
exception that they are unipotent. Further epige-
netic reprogramming events take place in germ
cells, including genome-wide DNA demethylation
and remodeling of retrotransposon-linked genes.
tissues, as well as to germ cells (Fig-
ure 1). To restrict their cell fate, PGCs
exhibit lineage-specific gene expression,
including Blimp1 and Nanos3 (Ohinata
et al., 2005; Tsuda et al., 2003). Of partic-
ular note for the maintenance of early unipotent germ cell lineage
is the presence of a Blimp1-Prmt5 repressive complex; Prmt5 is
a histone H2A/H4 symmetrical arginine 3 demethylase (H2A/
H4R3me2s) (Ancelin et al., 2006). During EG cell derivation,
Blimp1 is rapidly downregulated (Durcova-Hills et al., 2008),
which likely reverses restriction on the germ cell lineage, while
Prmt5 assumes another role in promoting pluripotency. The
Blipm1-Prmt5 complex translocates to the cytoplasm at E12.5
(Ancelin et al., 2006), precisely when the ability to generate EG
cells from PGCs ceases. Thus, the Blimp1-Prmt5 complex may
safeguard unipotency of early germ cells, but it may also have
a role in epigenetic reprogramming itself. These hypotheses are
testable predictions that will be interesting to tackle in the future.
It is known that humanESCs that resemble pluripotent epiblast
stem cells (EpiSCs) (Brons et al., 2007; Tesar et al., 2007) can
generate cells with characteristics resembling PGCs (Clark
et al., 2004). It is possible that the significance of epigenetic
reprogramming in PGCs may become evident by investigating
EpiSCs, which are derived from E5.5–E6.5 postimplantation
embryos. EpiSCs differ significantly from ESC/EG cells in their
overall transcription profile and in their epigenetic state (Brons
et al., 2007; Hayashi et al., 2008; Tesar et al., 2007), even though
this population also exhibits expression of key pluripotency-
specific genes (Figure 2A). However, EpiSCs have an inactive X
chromosome and possibly hypermethylation of CpG sequences
of some pluripotency genes, such as stella and Rex1/Zfp42.
EpiSCscanneither contribute to adult chimeras,whichprecludes
their contribution toPGCs in vivo (Brons et al., 2007), nor be easily
converted to ESCs (Guoet al., 2009). If PGCscanbederived from
EpiSCs in vitro and if thesePGCsundergo appropriate epigenetic
reprogramming, they may, in turn, be induced to give rise to EG
cells. These results would demonstrate that reprogramming in
PGCs is a route through which the EpiSC epigenome can be re-
modeled and perhaps reverted to the ICM/ESC-like pluripotent
state (Figure 2A). Thus, the epigenetic barrier that is created
during development of the epiblast and EpiScsmay be breached
during PGC development.494 Cell Stem Cell 4, June 5, 2009 ª2009 Elsevier Inc.
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The most significant epigenetic reprogramming event in the
germline is genome-wide DNA demethylation and extensive
histone modifications that take place in gonadal PGCs (Hajkova
et al., 2008). Though DNA demethylation does occur to some
extent during preimplantation development (Howlett and Reik,
1991; Monk et al., 1991), there is no process equivalent to the
reprogramming observed in germ cells reported in cells of other
lineages, and this process accounts for the complete erasure
and resetting of the epigenome in the germline. This specialized
reprogramming may account for the rare incidences of transge-
nerational inheritance of epimutations (Whitelaw and Whitelaw,





Figure 2. Impact of PGC-Mediate
Epigenetic Reprogramming on Pluripotent
Stem Cells
(A) Mouse ESCs (top) derived from ICM/PEct
exhibit an epigenetic status similar to mouse EG
cells because PGC-mediate reprogramming has
the potential to erase epigenetic memory of
epiblast. It is proposed that derivation of PGCs
from EpiSCs may similarly erase the epigenetic
memory of the latter. Human ESCs (bottom) may
lack the ICM/PEct reprogramming event observed
in the mouse ICM/PEct, making hESCs more like
the EpiESCs. However, epigenetic reprogramming
in human germ cells renders them responsive to
LIF-STAT3 signaling and, therefore, similar to
mouse ES/EG cells, which suggests equivalent
resetting of the epigenome in the mouse and
human germline.
(B) Experimentally generated pluripotent stem
cells may exhibit defects in their potential for
terminal differentiation and, thus, may not be
capable of development to term in tetraploid
host blastocysts. These limitations may result
from the presence of epigenetic defects retained
during an incomplete reprogramming process.
Epigenetic defects encountered in experimentally
generated pluripotent cells may be corrected
upon their transmission through the germline (top).
imprinted genes and retrotransposons,
such as LINE1, are remodeled appropri-
ately (Hajkova et al., 2002). Notably, there
is no strictly equivalent phenomenon in
PEct/ICM, in ESCs, or in other experimen-
tally derived pluripotent cells. The lack of
a similar remodeling of the genome in
the experimentally generated pluripotent
cells may affect their functional properties
(see below).
Evidence suggests that remodeling
of retrotransposon-associated and im-
printed genes in germ cells also con-
tributes to totipotency by restoring
the potential for subsequent fetal and
placental development. Genes associ-
ated with retrotransposable elements
include Peg10 and Rtl1 (also known as
Peg11), which are essential for placental
development (Ono et al., 2006; Sekita
et al., 2008). Several human placental
genes, such as Endothelin B receptor, Insl4, Leptin, Midline1,
and Pleiotrophin, are also associated with retrotransposable
elements (Rawn and Cross, 2008). It is likely that genome-wide
DNA demethylation exclusively in gonadal PGCs contributes to
resetting these genes and others that are critical for develop-
ment of the conceptus after fertilization.
Remodeling of the epigenetic status of retrotransposable
elements, however, may cause mutagenesis in the genome by
active transposition. Recent studies elegantly demonstrate that
small RNA pathways, such as piRNA (also known as gsRNA)
and endogenous siRNA, play a crucial role in suppressing the
expression of retrotransposons (Aravin et al., 2006; Girard
et al., 2006; Watanabe et al., 2006, 2008). Disruption of theseCell Stem Cell 4, June 5, 2009 ª2009 Elsevier Inc. 495
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but not that of PEct or ESCs, suggesting that germ cells possess
both the specific circumstance in which retrotransposons can be
activated and specific mechanisms to suppress them, which
imparts tolerance for these activities.
Recent studies also reveal characteristic remodeling of the
epigenetic status of Rhox genes, which were initially identified
as a gene cluster of the reproductive homeobox on the X chro-
mosome. Detailed analysis clearly revealed that expression of
these genes commences exclusively in PGCs at E12.5 PGCs
(Daggag et al., 2008), when massive DNA demethylation occurs.
Comparison of the epigenetic status of the Rhox gene cluster in
PGCs and in fetal and placental tissues will clarify the signifi-
cance of remodeling these genes in PGCs.
Implications of Germline-Specific Reprogramming
in Humans
Apart from the germline, epigenetic reprogramming also takes
place during the establishment of pluripotent cells in the ICM, as
exemplifiedby reactivation of the inactive paternal X chromosome
(Mak et al., 2004; Okamoto et al., 2004). Whether such an event
occurs in the human ICM is unclear. Notably, expression of Xist,
a noncoding RNA important for X inactivation, is apparently de-
tected from both parental alleles in human embryos and not just
from the paternal allele as in the mouse (Daniels et al., 1997;
Ray et al., 1997). It is possible that there may not be an epigenetic
reprogramming event in the human PEct/ICM consistent with that
seen in the mouse ICM (Figure 2A). If substantiated, this hypoth-
esis may explain why mouse ESCs differ from human ESCs; for
example, mouse female ESCs express two active X chromo-
somes, whereas the vast majority of human female ESCs retain
an inactive X chromosome (Dhara and Benvenisty, 2004; Shen
et al., 2007). In addition, hESCs more closely resemble mouse
EpiSCs than ESCs, and both of the former require bFGF/Activin
for their self-renewal, whereas mouse ESCs/EG cells require
LIF/STAT3 signaling to retain their pluripotent state (Niwa et al.,
1998). Whether the observed differences in patterns of X inactiva-
tion and the signaling requirements of mouse and human ESCs
are functionally connected remains to be determined. However,
it is possible that the ICM/PEct in human embryos may continue
development toward a postimplantation epiblast-like stage during
the derivation of hESC from blastocysts.
Based on the available evidence, it does appear that the
extensive epigenetic reprogramming observed in mouse germ
cells may also occur in the human, given that extensive DNA
demethylation would be required to reset the imprints and for
X reactivation. That thesemodifications occur seems particularly
likely because human EG cells, unlike hESC, are dependent on
LIF/STAT signaling (Figure 2A) (Shamblott et al., 1998). Sper-
matogonia-derived human pluripotent stem cells are also similar
to mouse ES/EG cells (Conrad et al., 2008). The nature of epige-
netic reprogramming events in human germ cells could be exam-
ined in PGCs derived from hESC, and parallel experiments may
also be possible with mouse EpiSCs in vitro.
Perspective on Experimentally Induced Pluripotency
A classical approach to restore totipotency/pluripotency in
somatic nuclei is by transplantation into an oocyte (SCNT)
(Campbell et al., 1996; Wakayama et al., 1998). The transferred496 Cell Stem Cell 4, June 5, 2009 ª2009 Elsevier Inc.somatic nuclei are exposed to reprogramming factors in the
oocyte, and as a result, they may acquire totipotency. Further-
more, during subsequent development of such reconstituted
embryos to the blastocyst stage, donor nuclei may also undergo
reprogramming in the ICM. In spite of this two-step reprogram-
ming of somatic nuclei in early embryos, the resulting concep-
tuses often show both fetal and placental abnormalities,
suggesting that neither the oocyte nor the ICM has the compre-
hensive potential to reset the epigenetic state of the somatic
nucleus (Bao et al., 2005; Bortvin et al., 2003). Many of these
defects are, however, corrected upon transmission through the
germline (Shimozawa et al., 2002; Tamashiro et al., 2002),
demonstrating the comprehensive nature of epigenetic reprog-
ramming upon passage through the germ cell lineage
(Figure 2B). Though some of the epigenetic defects could be
erased during epigenetic reprogramming in the ICM, rather
than in germ cells, any defects present in the trophectoderm
and other extraembryonic lineages would remain uncorrected.
The experimentally generated human pluripotent stem cells
(hESCs) and iPSC may show even greater defects compared
to the mouse because, as discussed above, it is unclear whether
human cells experience an equivalent reprogramming event as
observed in the ICM of the mouse. In any case, it seems that
the extensive epigenetic reprogramming and resetting of the epi-
genome observed in the germline, including genome-wide DNA
demethylation as well as wide-ranging histone modifications, do
not occur in the oocyte or in the ICM.
Germline Reprogramming and the iPSC
The most important recent advance toward restoring pluripo-
tency in somatic cells comes from Yamanaka’s work using
transcription factors, including Oct4, Sox2, Klf4, and c-Myc, to
convert somatic cells into iPSCs that appear overtly equivalent
to pluripotent ESCs (Takahashi and Yamanaka, 2006). Consider-
able attention has been paid to the low frequency of the deriva-
tion of iPSCs, the protracted nature of the process, and some of
the key properties of these cells (Hochedlinger and Plath, 2009).
From our perspective, however, the most important remaining
question is how closely do iPSCs truly resemble ESCs derived
from normal blastocysts.
To generate iPSCs, the pluripotency-specific transcriptional
factors introduced into somatic cells probably help to establish
a new genetic network that evidently approximates the authentic
pluripotency network, although it cannot be excluded that subtle
yet important differences may be present. However, the genera-
tion of iPSCs from somatic cells does not appear to require
systematic reversal of the entire developmental program that
originally resulted in all of the diverse somatic cells with distinct
phenotypes. Differentiation of somatic cells requires robust
silencing of genes and regulatory elements that are not required
in specific cell types. It is possible that epigenetic modifications
associated with such silent genes that are robustly repressed
in specific differentiated cells by DNAmethylationmay be difficult
to reverse, as is the case with methylation of imprinted genes,
which could make some key regulatory elements inaccessible
to tissue-specific binding factors (Xu et al., 2007). This hypothesis
is plausible, given that pluripotency is the property being selected
for in these experiments rather than the ability of the newly estab-
lished iPSC to undergo terminal differentiation to a specific
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iPSCs, in that some genes that are silenced in specific cell types
may remain silenced, and the residualmemorymarksmay only be
erased upon transmission through the germline. Therefore, it is
essential to carry out comprehensive epigenetic analysis of
iPSCs, for example, by using genome-wide methylation analysis
by methylDip (Farthing et al., 2008), in carefully controlled exper-
iments to rigorously address the hypothesis that iPSCs retain
tissue restriction patterns from their parental cells.
The most stringent test to establish whether cells, such as
iPSCs, are indeed pluripotent is to demonstrate that full-term
embryos can be derived exclusively from the putative pluripotent
cells. To do so, the candidate donor cells are introduced into
‘‘tetraploid’’ host blastocysts, in which the donor cells do not
contribute to placental development. Though it remains possible
that iPSC do possess this potential, no live young have yet been
reported from iPSCs in any such experiments, even though they
have in some instances reached an advanced stage of E14 of
gestation (Meissner et al., 2007; Woltjen et al., 2009). Indeed,
one could predict that iPSCs might display relatively greater
defects at later stages during terminal differentiation of somatic
lineages, with the notable exception of germ cells and gametes,
given that all epigenetic modifications are erased and reset in
this lineage (Figure 2B). Very careful systematic epigenetic anal-
ysis, together with a comprehensive examination of differentia-
tion and precise distribution of iPSCs into all of the tissues in
chimeric adults, could reveal their true developmental potential.
Following this line of reasoning, one might also expect that the
nature of the residual epigenetic memory would depend on the
original somatic cells used in these experiments, notwith-
standing the stochastic nature of the process. It is crucial also
to confirm rigorously whether iPSC-derived differentiated cells
are equivalent to normal terminally differentiated cells. The
proposed use of terminally differentiated iPSCs in cell therapy
and disease models requires them to be phenotypically and
physiologically identical to the in vivo terminally differentiated
cells. We predict that any residual epigenetic memory in iPSCs
would be erased as the epigenome is reset in the germline
(Figure 2B). Notably, transdifferentiation of closely related cell
types would be predicted to be less affected by the residual
epigenetic memory because these cells would share many of
their key epigenetic properties (Zhou et al., 2008).
It is known from several studies that mouse ESCs exhibit
functional and epigenetic heterogeneity (Enver et al., 2009; Graf
and Stadtfeld, 2008; Hayashi et al., 2008). It is possible that
such heterogeneitymay be prevalent in experimentally generated
pluripotent cells, which may be accentuated in human iPSCs, as
they lack the ICM-like reprogramming event that we have
describedhere.Under ideal conditions, following reprogramming,
each cell should exhibit an equivalent epigenetic state and iden-
tical potential for pluripotency, which may not be the case. For
example, during establishment of iPSCs, only a minority of trans-
duced cells are converted to pluripotency and selected under the
applied culture conditions, and it is unknown whether all of these
cells acquire identical properties. Indeed, even the process of re-
deriving ‘‘secondary’’ iPSCs using conditional reprogramming
vectors remains inefficient (Jaenisch and Young, 2008; Maherali
and Hochedlinger, 2008). It is possible that the protracted nature
of this procedure could result in daughter cellswith diverse epige-netic states. This possibility can also be evaluated by rigorous
clonal analysis of iPSCs for their phenotypic and epigenetic prop-
erties. Resetting of the epigenome in thegermlinemay not only be
extensive, but it also benefits from rigorous in vivo selection, as
seen during spermatogenesis (Ueno et al., 2009).
Conclusions
Based on the existing evidence, we suggest that the most
comprehensive process of epigenetic reprogramming that
ensures authentic pluripotency occurs upon passage through
the germline. The wide-ranging erasure of epigenetic modifica-
tions, including DNA demethylation, ensures removal of most,
if not all, of the extraneous epigenetic information. This conver-
sion apparently does not occur in the experimentally restored
pluripotent state. In the mouse, the form of reprogramming
that takes place in the ICM provides a possibility for approaching
the authentic pluripotent state, but even so, the result is often
variable, owing to the stochastic nature of the process (Bortvin
et al., 2003). hESCs may be more compromised in terms of their
functional pluripotency, as these populations evidently lack the
ICM-specific reprogramming step. This distinction sets hESCs
apart from mESCs and may account for the relatively heteroge-
neous nature of hESCs, as has been observed with mEpiSCs.
Greater understanding of the process of germline-specific
reprogramming may thus provide additional tools to advance
stem cell research. Uncovering the details of this process is
particularly important, given that the use of experimentally
generated differentiated cells from pluripotent cells, including
iPSCs, has been proposed for widespread use in cell therapy
and to develop disease models for drug discovery.
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